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Abstract
Background: The ability of catecholamines to stimulate bacterial growth was first demonstrated
just over a decade ago. Little is still known however, concerning the nature of the putative bacterial
adrenergic and/or dopaminergic receptor(s) to which catecholamines (norepinephrine,
epinephrine and dopamine) may bind and exert their effects, or even whether the binding
properties of such a receptor are similar between different species.
Results: Use of specific catecholamine receptor antagonists revealed that only α, and not β,
adrenergic antagonists were capable of blocking norepinephrine and epinephrine-induced growth,
while antagonism of dopamine-mediated growth was achieved with the use of a dopaminergic
antagonist. Both adrenergic and dopaminergic antagonists were highly specific in their mechanism
of action, which did not involve blockade of catecholamine-facilitated iron-acquisition. Use of
radiolabeled norepinephrine suggested that the adrenergic antagonists could be acting by inhibiting
catecholamine uptake.
Conclusion: The present data demonstrates that the ability of a specific pathogen to respond to
a particular hormone is dependent upon the host anatomical region in which the pathogen causes
disease as well as the neuroanatomical specificity to which production of the particular hormone
is restricted; and that both are anatomically coincidental to each other. As such, the present report
suggests that pathogens with a high degree of exclusivity to the gastrointestinal tract have evolved
response systems to neuroendocrine hormones such as norepinephrine and dopamine, but not
epinephrine, which are found with the enteric nervous system.
Background
During the past decade, there has been increasing recogni-
tion that microorganisms can actively respond to the
host's neurophysiological hormonal output through the
utilization of neuroendocrine hormones as environmen-
tal cues to initiate growth and pathogenic processes [1,2].
The study of such microbial-neuroendocrine hormone
interaction has been termed microbial endocrinology
[1,2]. To date, the most studied neuroendocrine hormo-
nal family from a microbial endocrinology perspective
has been the catecholamines due to their central role in
stress-mediated phenomena such as traumatic injury
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involving the sudden release of large amounts of catecho-
lamines concomitant to bacterial exposure [3,4]. The cat-
echolamines represent a group of organic compounds
derived from tyrosine and consisting of a benzene ring
with two adjacent hydroxyl groups and an opposing
amine side chain. In metazoa, the catecholamines are
responsible for a number of signalling phenomena and
are generally associated with stressful events that result in
high circulatory levels that prepare the organism physio-
logically for physical activity such as the "fight-or-flight"
response.
Reports dating back over 70 years have described an asso-
ciation between catecholamines and microbial infectivity
purportedly due to catecholamine-induced immune sup-
pression [2]. The first mechanistic demonstration that cat-
echolamines could directly influence bacterial growth,
however, was not until 1992 when Lyte and Ernst used a
serum-based medium to demonstrate that exposure to
catecholamines induced log-fold increases in growth of a
limited number of gram-negative pathogens [5]. The
examination of a much larger set of clinical isolates by
Freestone et al showed that recognition of catecholamines
was widespread amongst Gram-positive and negative bac-
teria [6]. Subsequent reports have extended the range of
stress hormone-responsive bacteria [7], as well as demon-
strating a further role for catecholamines in the produc-
tion of virulence-associated factors such as toxins [8] and
adhesins [9], biofilm formation [10], and quorum sensing
[11]. The question as to whether such direct microbial-cat-
echolamine interactions occur via a receptor-mediated
process has, however, remained controversial. The most
likely explanation for these conflicting reports (as
described below) is that the examination of a putative
receptor-mediated process in bacteria has relied upon
observations from mammalian systems where the identi-
fication and classification of cellular catecholamine recep-
tors has lead to treatments for a variety of human disease
conditions extending from hypertension to depression. As
such, experimental approach has largely been dictated by
the availability of reagents that have been developed for
use in mammalian systems.
In mammals, the biochemical pathway for the synthesis
of catecholamines is L-dopa (most commonly from food-
borne sources) → Dop → NE → Epi. NE and Dop-con-
taining sympathetic nerve terminals are distributed widely
throughout the body, including the intestinal tract where
they make up part of the enteric nervous system (ENS)
[12]. Indeed, half of the NE present within the mamma-
lian body is synthesized and utilized within the ENS. Epi,
on the other hand, is principally produced by the adrenal
glands on the kidneys and is not present within the ENS
since no biosynthetic pathways have ever been found
throughout the entire length of the GI tract [12]. NE and
Epi bind to adrenergic-type receptors while Dop binds to
dopaminergic-type receptors. The adrenergic receptors are
classified into 2 major families, α and β, with a number of
receptor subtypes being increasingly identified. Similarly,
substantial heterogeneity of the dopamine receptor has
been described, with at least 5 receptor types currently rec-
ognized [13]. Importantly, NE and Epi are able to interact
and stimulate more than one adrenergic receptor family
since NE can stimulate both α and β1, but not β2, adrener-
gic receptors. Dopamine can also interact with any of the
D1–D5  receptor subtypes. While the availability of a
number of highly specific antagonists has enabled the elu-
cidation of the physiological role of the various receptor
types and subtypes, this work has been almost exclusively
carried out in mammalian model systems. Characteriza-
tion of adrenergic receptors in non-mammalian systems
utilizing pharmacological reagents developed for mam-
malian systems have been reported for Tetrahymena pyri-
formis [14] and Trypanosoma cruzi [15].
In bacteria, the initial search for a catecholamine receptor
was carried out by Lyte and Ernst, who examined the abil-
ity of a range of concentrations of 3 α and β adrenergic
receptor antagonists to block the ability of NE to modu-
late growth of several Gram-negative enteric species [16].
Since these antagonists had little effect on blocking cate-
cholamine growth induction, it was concluded that a non-
α, non-β type adrenergic receptor was present in Gram-
negative bacteria. More recently, Sperandio et. al. [17]
revisited the concept of a specific bacterial receptor for cat-
echolamines, initially suggested by Lyte and Ernst [16],
and showed that an α and β adrenergic antagonist could
inhibit Epi- and NE-induced LEE gene and flagella expres-
sion in Escherichia coli O157:H7 [16,17]. The putative
adrenergic receptors were identified as the QseBC and
QseEF two component regulators that control flagella and
LEE expression, respectively [11] and which were also
thought to have dual specificity for the luxS-dependent AI-
3 [17]. A more recent report [18] used in vitro constructs
to demonstrate that NE and Epi could bind to the E. coli
O157:H7 QseC sensor kinase and that the α adrenergic
antagonist phentolamine but not the β antagonist pro-
pranolol could prevent catecholamine binding. Interest-
ingly, the antagonist specificity of QseC appears to differ
markedly between these two reports since in the prior
study [17] the same research group used an in vivo model
to report that QseC had both α and β specificity, while the
latter  in vitro study states that QseC possesses only α
adrenergic specificity [18].
In order to resolve these prior conflicting reports, the
present study was designed to provide a more definitive
examination of the presence and nature of a putative
adrenergic/dopaminergic receptor-based mechanism in
bacterial-catecholamine interactions. A pharmacologicalBMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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approach employing a wider spectrum of adrenergic
antagonists than those used in previous studies [16,17]
was utilized to examine the specificity of bacterial cate-
cholamine responsiveness in three major enteric patho-
gens. Additionally, antagonist to agonist ratios over a
larger concentration range than previously reported in the
literature for bacteria was also employed. As previous
reports had not examined whether bacterial responses to
dopamine were receptor-mediated, we further investi-
gated the effects of a range of dopaminergic antagonists
on dopamine-induced effects on bacterial growth.
Results
Antagonism of catecholamine-induced bacterial growth by 
adrenergic and dopaminergic receptor antagonists
Previous reports, which have utilized small numbers of
eukaryotic receptor antagonists, often with limited dose-
response information, have produced conflicting results
regarding the existence of a putative bacterial catecho-
lamine receptor(s) [16,17]. As shown in Table 2, we uti-
lized an extensive range of antagonists, whose receptor
specificity is shown in Table 1, which were tested over a
wide dose response range. It is important to note that
these bacterial pharmacological experiments were initi-
ated with population densities of less than 102 CFU per ml
in order to more closely mimic the numbers of cells likely
to be involved at the initial stages of infection. The data in
Table 2 demonstrate that the non-selective β-adrenergic
receptor antagonist propranolol, which others had previ-
ously shown to block Epi responsiveness in E. coli
O157:H7 [17] had no effect on the ability of NE, Epi or
Dop to induce growth in any of the 3 bacterial species we
tested, which included an E. coli O157:H7. Similar nega-
tive results were obtained with a second non-selective β-
adrenergic receptor blocker labetalol. In contrast to the β-
adrenergic receptor antagonists, the α-adrenergic antago-
nists phentolamine, phenoxybenzamine and prazosin
were all able to inhibit growth induction by Epi and NE
by up to three or more log-orders, in a concentration-
dependent manner, as compared to control cultures not
supplemented with antagonist (P < 0.0001) (Table 2).
Examination of the kinetics of the α-adrenergic antago-
nist-induced blockade of growth induction by the cate-
cholamines demonstrated that the order of addition of
catecholamine and α-antagonist to the cultures was not
important. However, the continuing presence of the
antagonist during the culture period was required in order
to observe maximal inhibition of catecholamine-induced
growth, thereby indicating that the inhibition observed
was not due to an irreversible binding of the α-antagonist.
None of the α or β antagonists when tested alone induced
growth of any of the bacterial strains tested even at con-
centrations as high as 500 μM. Furthermore, addition of
Fe in the form of Fe(NO3)3 to catecholamine-supple-
mented cultures containing the α-antagonists overcame
the antagonist blockade of growth induction (Table 2).
This indicates that the growth inhibition by α-adrenergic
receptor antagonists was not due to any cellular toxicity of
the antagonist, but instead represents a specific antago-
nism of the bacterial response to NE and Epi. Additional
experiments showed that the specific growth phase of the
cultures (stationary or exponential) from which bacteria
were obtained for the initial inocula in experimental cul-
tures did not influence the potency profile of the α-antag-
onists. However, the initial population density of the
bacterial cultures was relevant, as the cut off level of the
antagonism effect in serum-SAPI medium was at approxi-
mately 105 CFU per ml for all three species (this represents
the cell density at which catecholamine-independent
growth occurs). Increasing the concentration of the cate-
cholamine reduced the inhibitory effect of the adrenergic
antagonists (Table 3) indicating that the inhibition
observed is competitive.
Interestingly, results presented in Tables 2 and 3 also
reveals that the α- or β-adrenergic antagonists tested
showed very little inhibition of bacterial growth responses
to Dop. From the eukaryotic receptor perspective this
would not be surprising given that dopamine does not
operate through either α or β-adrenergic receptors, but
instead by interaction with specific dopamine receptors
which are not targets for α or β-adrenergic antagonists
[13]. Previous reports from our laboratories have shown
that Dop modulates growth in prokaryotes through the
provision of iron from the host iron binding proteins Tf
and Lf in a manner similar to that shown by NE and Epi
[3,19,20]. We therefore investigated whether dopaminer-
gic antagonists had any effect on E. coli O157:H7, S. enter-
ica and Y. enterocolitica growth responses to Dop.
Inclusion of the non-selective antagonist haloperidol, and
the D1 specific antagonist raclopride in Dop-supple-
mented serum-SAPI assays did not alter the ability of Dop
to induce growth in any of the 3 bacterial species (data not
shown); however, the D2 receptor antagonist chlorpro-
mazine was able to block growth responses to Dop in all
3 species by up to 3 log orders (Table 4) (P < 0.0001). In
contrast, chlorpromazine had no significant effect upon
either NE or Epi induction of growth. Addition of' Fe to
Table 1: Specificity of receptor antagonists and affinities.
Antagonist Specificity
Phentolamine α-Adrenergic (α1=α2)
Phenoxybenzamine α-Adrenergic (α1=α2)
Prazosin α-Adrenergic (α1)
Labetalol α and β Adrenergic (α1,β)
Propranolol β-Adrenergic (β1=β2)
Chlorpromazine Dopaminergic (D2 > D1)
Haloperidol Dopaminergic (non-selective)
Raclopride Dopaminergic (D1)BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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Table 2: Antagonism of catecholamine-induced growth responsiveness
Antagonist Concentration (μM)
Species Antagonist CA 0 0.1 1 10 20 50 75 100 200 bN/A
E. coli O157:H7 Phentolamine NE a 8.29 8.23 8.04 7.75 7.48 6.65 5.88 5.74 5.69 4.14
NE+Fe c 8.30 8.19
Epi 8.20 8.12 8.21 8.01 7.88 7.32 6.46 5.94 5.84
Epi+Fe 8.19 8.04
Dop 8.16 8.11 8.12 8.16 8.00 7.92 7.83 7.78 7.69
Phenoxybenzamine NE 8.25 8.13 8.12 7.62 7.47 6.90 5.51 4.26 4.00 4.34
NE+Fe 8.19 8.05
Epi 8.13 8.09 8.00 8.02 7.76 7.00 6.46 5.90 5.81
Epi+Fe 8.20 8.04
Dop 8.16 8.16 8.15 8.11 8.12 8.10 8.00 7.99 7.87
Prazosin NE 8.25 8.25 8.03 8.00 7.78 7.31 6.72 5.85 5.47 4.16
NE+Fe 8.27 8.28
Epi 8.12 8.16 8.13 8.08 7.94 7.81 6.43 6.12 5.66
Epi+Fe 8.16 8.10
Dop 8.13 8.12 8.11 8.09 8.12 8.10 8.08 8.04 8.00
Propranolol NE 8.14 8.07 8.08 8.00 8.08 8.03 8.00 7.99 7.90 4.16
Epi 8.13 8.11 8.14 8.10 8.21 8.12 8.13 8.08 7.88
Dop 8.15 8.15 8.10 8.10 8.07 8.06 8.03 8.06 8.07
S. enterica Phentolamine NE 8.25 8.25 8.00 7.94 6.94 6.83 5.83 5.80 5.50 4.88
Epi 8.07 8.04 8.01 7.93 7.61 6.90 5.66 5.07 4.68
Dop 8.09 8.07 8.05 8.12 8.12 8.04 7.99 7.82 7.34
Phenoxybenzamine NE 8.27 8.23 8.20 8.14 7.90 6.62 6.41 6.34 5.18 4.89
Epi 8.15 8.14 8.17 8.16 7.87 7.04 6.94 6.77 5.97
Dop 8.10 8.11 8.10 8.07 8.09 8.07 8.04 8.01 8.00
Prazosin NE 8.17 8.16 8.10 8.04 7.74 7.48 6.94 5.41 5.00 4.87
Epi 8.14 8.14 8.16 8.14 8.10 7.82 7.33 6.95 6.77
Dop 8.12 8.15 8.12 8.10 8.12 8.07 7.07 8.03 8.05
Propranolol NE 8.15 8.14 8.10 8.07 8.19 8.16 8.06 7.98 7.75 4.89
Epi 8.18 8.19 8.15 8.08 8.16 8.08 8.08 8.03 8.01
Dop 8.16 8.09 8.12 8.14 8.10 8.09 8.12 8.06 8.05
Y. enterocolitica Phentolamine NE 8.30 8.29 8.26 7.96 7.54 6.87 6.52 5.99 5.99 3.83
Dop 8.11 8.06 8.11 8.08 8.11 8.08 8.07 8.03 8.01
Phenoxybenzamine NE 8.28 8.32 8.23 7.86 7.00 6.81 6.26 5.77 5.62 3.90
Dop 8.09 8.07 8.11 8.10 8.08 8.07 6.10 8.03 7.99
Prazosin NE 8.25 8.21 8.15 8.03 7.47 6.95 6.64 6.50 5.88 3.82
Dop 8.05 8.07 8.08 8.07 8.08 8.06 8.04 8.01 7.94
Propranolol NE 8.26 8.22 8.24 8.20 8.19 8.22 8.07 8.04 7.99 4.00
Dop 8.05 8.08 8.09 8.11 8.12 8.07 8.08 8.03 8.04
E. coli O157:H7, S. enterica and Y. enterocolitica were inoculated at approximately 102 CFU/ml into duplicate 1 mL aliquots of serum-SAPI containing 
the catecholamines (CA) NE, Epi and Dop plus the concentrations of antagonists shown in the table, and incubated for either 18 hours (E. coli and S. 
enterica) or 40 hours (Y. enterocolitica), and enumerated for growth (a, expressed as log-10 CFU/ml) as described in Materials and Methods. Growth 
levels of non-catecholamine supplemented cultures (b, N/A) are shown for comparison purposes. NE and Dop were used at 50 μM, and Epi and Fe 
(Fe(NO3)3) at 100 μM. Note that catecholamine antagonist assays containing Fe (c) were also performed for S. enterica and Y. enterocolitica and 
confirmed, by no effect on bacterial growth induction by iron, that the antagonists were not toxic (data not shown). The results shown are 
representative data from at least three separate experiments; all data points showed variation of less than 5%. Antagonist supplemented cultures 
showed statistically significant decreases in growth levels (P < 0.001) as compared with control (catecholamine only supplemented) cultures.BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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dopamine-supplemented E. coli O157:H7, S. enterica and
Y. enterocolitica cultures containing chlorpromazine
restored growth, again indicating that the inhibition
observed was not due to toxicity of the antagonist (Table
4). Addition of chlorpromazine alone did not induce
growth in any of the 3 strains tested, while increasing the
concentration of the catecholamine reduced the inhibi-
tory effect of the chlorpromazine therefore indicating that
the dopaminergic antagonism observed is competitive
(data not shown). The non-selective dopamine receptor
agonist apomorphine did not induce growth, and was
also without effect on dopamine-mediated growth induc-
tion.
Mechanistic investigations of the adrenergic and 
dopaminergic antagonist inhibition of catecholamine 
growth responsiveness
As previously mentioned, one aspect of the mechanism by
which catecholamines induce growth relates to their abil-
ity to facilitate iron removal from Tf and Lf [3,10,20,21].
Table 3: α-Adrenergic and dopaminergic antagonist inhibition of norepinephrine, epinephrine and dopamine-mediated growth 
induction is competitive
Species Catecholamine μM a No antagonist Chlorpromazine Phentolamine Phenoxybenzamine Prazosin
NE N/D
E. coli O157:H7 b 0 4.62 3.91 4.6 4.00
5 6.77 4.64 4.66 4.77
50 8.03 5.19 5.02 5.75
100 8.40 5.84 6.00 6.82
200 8.42 7.33 7.42 7.88
500 8.41 8.24 8.33 8.24
Epi N/D
5 4.92 4.00 3.83 4.08
50 7.28 5.19 4.32 5.72
100 8.05 5.76 5.75 6.82
200 8.24 7.25 7.95 7.85
500 8.00 8.05 8.08 8.09
Dop N/D N/D N/D
5 5.82 4.68
50 8.03 5.90
100 8.36 6.53
200 8.13 6.83
300 8.06 7.60
Y. enterocolitica NE N/D
0 3.87 3.83 3.83 3.82
5 4.65 4.00 4.32 4.47
50 8.03 5.75 5.71 5.74
100 8.09 6.78 5.82 6.56
200 8.04 7.00 7.54 7.94
500 8.00 8.02 8.05 8.00
Dop N/D N/D N/D
5 5.66 4.62
50 7.47 5.19
100 8.11 6.12
200 8.02 6.50
300 7.78 7.95
E. coli O157:H7 and Y. enterocolitica were inoculated at approximately 102 CFU/ml into duplicate 1 mL aliquots of serum-SAPI containing either no 
additions (No antagonist, 0) or only the NE, Epi and Dop concentrations shown (No antagonist). To determine if increasing the catecholamine 
concentration overcame antagonists effects, the same concentrations of NE or Epi or Dop were incubated with 200 μM additions of the 
dopaminergic antagonist chlorpromazine, or the α-antagonists phentolamine, phenoxybenzamine and prazosin. Note that usage of Dop was limited 
to 300 μM because higher concentrations were inhibitory to Y. enterocolitica (See Figure 1). Cultures were incubated for either 18 hours (E. coli 
O157:H7) or 40 hours (Y. enterocolitica), and enumerated for growth (a, expressed as log-10 CFU/ml) as described in Materials and Methods. Growth 
levels of non-catecholamine supplemented cultures (0, b) are shown for comparison purposes. N/D – not determined. The results shown are 
representative data from two separate experiments; all data points showed variation of less than 3%. α-adrenergic antagonist-supplemented NE and 
Epi cultures showed statistically significant decreases in growth levels (P < 0.001) as compared with control (catecholamine-only supplemented) 
cultures. Similar results to those shown for E. coli O157:H7 were also obtained for S. enterica.BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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Using E. coli strains deficient in enterobactin synthesis
and uptake (entF and tonB mutations), we [19] and others
[22] have shown that for Gram-negative bacteria, a func-
tional siderophore system is an integral element in the
mechanism by which bacteria assimilate the Tf/Lf-com-
plexed iron made available by the interaction of the cate-
cholamine with the host iron binding protein. We
therefore hypothesized that a possible mechanism by
which the α-adrenergic antagonists were blocking cate-
cholamine-induced bacterial growth might be through
interference with the catecholamine-mediated uptake of
Fe from Tf. The ability of α-adrenergic antagonists to spe-
cifically block catecholamine-mediated uptake of Fe from
Tf was examined with the use of 55Fe-labelled Tf as
described in Materials and Methods. As shown in Table 5,
bacterial 55Fe uptake assays were performed in the pres-
ence of NE and Epi and were challenged with concentra-
tions of phentolamine, phenoxybenzamine or prazosin
which had been shown in Table 2 to inhibit the ability of
NE and Epi to induce growth by at least 2 log orders. The
results of such 55Fe uptake assays clearly demonstrated
that the α-adrenergic antagonists caused no significant
reduction in the ability of the catecholamines to mediate
bacterial 55Fe acquisition from 55FeTf, and that only the
addition of Fe affected the amount of 55Fe that was inter-
nalized by each of the bacterial strains (Table 5) (due to
the repression of Fe-regulated siderophore synthesis)
[19,22]. The β-adrenergic antagonists propranolol and
labetalol also had no effect on catecholamine-mediated
55Fe uptake from 55FeTf (data not shown). We used a sim-
ilar methodology to determine whether dopaminergic
antagonists affected dopamine-mediated deliver of 55Fe
from 55FeTf (Table 6). Concentrations of chlorpromazine
which were markedly inhibitory to dopamine stimulated
growth induction also had no significant effect on uptake
of 55Fe from 55FeTf with only addition of Fe causing any
reduction in bacterial 55Fe acquisition (due again presum-
ably to repression of siderophore synthesis) [19,22].
Examination of the effect of α-adrenergic antagonists on 
norepinephrine uptake
Adrenergic antagonists classically exert their effects on
eukaryotic cells by competitively binding to adrenergic
receptors (with the exception of phenoxybenzamine,
which binds irreversibly) [23]. Previously, we demon-
strated that NE is internalized by bacteria during the NE-
growth induction process [21], which prompted us to
investigate whether the mechanism by which the adrener-
gic antagonists were acting might involve blocking the
entry of NE into the bacterial cell. Figure 1 shows the
uptake of 3H-NE in high cell density cultures of E. coli
O157:H7, S. enterica and Y. enterocolitica treated with a
Table 4: Antagonism of dopamine-induced growth responsiveness
Chlorpromazine Concentration (μM)
Species CA 0 0.1 1 10 20 50 75 100 200 300 bN/A
E. coli O157:H7 Dop a 8.00 7.99 7.88 7.82 7.73 7.32 6.75 6.10 5.37 4.98 4.14
Dop+Fe 8.12 8.16
NE 8.30 8.22
NE+Fe 8.25 8.31
Epi 8.06 7.88
Epi+Fe 8.16 8.09
S. enterica Dop 7.95 7.94 7.88 7.82 7.75 7.67 7.52 7.01 6.17 4.96 4.92
Dop+Fe 8.16 8.14
NE 8.09 7.99
NE+Fe 7.99 8.20
Epi 8.00 7.88
Epi+Fe 8.21 8.16
Y.enterocolitica Dop 8.00 8.00 8.01 8.00 7.99 7.31 7.07 6.94 5.35 5.04 3.90
Dop+Fe 8.05 8.03
NE 8.05 7.96
NE+Fe 8.06 8.02
Epi N/D N/D
Epi+Fe N/D N/D
E. coli O157:H7, S. enterica and Y. enterocolitica were inoculated at approximately 102 CFU/ml into duplicate 1 mL aliquots of serum-SAPI containing 
the catecholamines (CA) and concentrations of chlorpromazine shown and incubated and enumerated for growth levels (a, expressed as log-10 CFU/
ml)as described in Materials and Methods. NE and Dop were used at 50 μM, and Epi and Fe (Fe(NO3)3) at 100 μM. The results shown are 
representative data from three separate experiments; data points typically showed variation of less than 3%. Growth levels of non-catecholamine 
supplemented cultures (b, N/A) are shown for comparison purposes. Chlorpromazine-supplemented cultures showed statistically significant 
decreases in growth levels (P < 0.001) as compared with control (catecholamine-only supplemented) cultures.
N/D, not determined.BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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concentration of α-adrenergic antagonist that had been
shown to inhibit growth induction by NE (Table 2). The
data shown reveals that for all 3 species uptake of 3H-NE
was significantly reduced by the presence of the antago-
nist (P  < 0.001), though in no case was it completely
blocked.
Discussion and Conclusion
The present report provides the most comprehensive
study to date regarding the possible role of adrenergic-
and dopaminergic-type receptors in catecholamine-
induced bacterial growth. The results presented provide
evidence for the involvement of bacterial response sys-
tems that resemble α, but not β, adrenergic receptors in
the mechanism of NE and Epi growth induction of Gram-
negative bacteria. Evidence was also obtained for the
involvement of a bacterial response system with D2
dopaminergic-like specificity in dopamine-mediated
growth induction.
In the vertebrate nervous system the adrenergic receptors
for NE and Epi were originally classified as belonging to
either α or β subtypes, but subsequent research over the
last 50 years has revealed that each subtype in fact repre-
sents a receptor family that is comprised of a number of
subtypes [23]. Although NE differs from Epi only by the
lack of a methyl substitution in the amino group, a signif-
icant and defining physiological distinction between the
two can be found in their relative ability to stimulate α
and β receptors. Epi, which is principally produced in the
adrenal medulla, is a potent agonist for α, β1 and β2 adren-
ergic receptors. NE which is produced by neurons of the
sympathetic and enteric nervous systems, can stimulate
both α and β1, but to a much lesser degree β2, adrenergic
Table 6: Chlorpromazine does not inhibit the ability of dopamine to mediate bacterial uptake of Tf-complexed iron.
Uptake of 55 Fe from 55 Fe-Tf (CPM)
Culture Conditions Y. enterocolitica E. coli S. enterica
No additions (control) 125 (10) 1477 (7) 595 (72)
300 μM Chlorpromazine 231 (3) 1407 (31) 646 (11)
50 μM Dopamine 2083 (120) 24768 (750) 31877 (684)
50 μM Dopamine plus 100 μM Chlorpromazine 2239 (17) 23254 (308) 36937(217)
50 μM Dopamine plus 200 μM Chlorpromazine 2160 (152) 25945 (445) 34934 (638)
50 μM Dopamine plus 300 μM Chlorpromazine 1946 (15) 22434 (17) 33545 (131)
50 μM Dopamine plus 100 μM Fe 932 (11) 4757 (69) 3064 (77)
100 μM Fe 682 (2) 3064 (77) 2783 (28)
The table shows dopamine-mediated bacterial uptake assays of 55Fe from 55Fe-labelled transferrin in the presence of concentrations of 
chlorpromazine inhibitory to dopamine-mediated growth induction, and were performed as described in the legend to Table 5. The values shown 
represent the means of bacterial 55Fe incorporation from triplicate 1 ml uptake assays; standard deviations are shown in brackets. There were no 
significant differences in viable counts between control and test cultures.
Table 5: α-Adrenergic antagonists do not inhibit the ability of catecholamines to -mediate bacterial uptake of Tf-complexed iron.
Uptake of 55 Fe from 55 Fe-Tf (CPM)
Culture Conditions Y. enterocolitica E. coli O157:H7 S. enterica
No additions (control) 363 (14) 848 (23) 910 (33)
50 μM NE 2736 (13) 21343 (1185) 22867 (848)
50 μM NE plus 200 μM phentolamine 2375 (98) 22333 (1154) 24843 (141)
50 μM NE plus 200 μM phenoxybenzamine 2482 (93) 20205 (1058) 22106 (676)
50 μM NE plus 200 μM prazosin 3133 (37) 23189 (1185) 21109 (625)
50 μM NE plus 100 μM Fe 613 (16) 3870 (57) 6617 (246)
100 μM Epi 1759 (101) 23975 (1164) 21006 (1045)
100 μM Epi plus 200 μM phentolamine 2133 (37) 28301 (262) 21991 (827)
100 μM Epi plus 200 μM phenoxybenzamine 1987 (37) 22151 (1148) 21452 (208)
100 μM Epi plus 200 μM prazosin 1887 (104) 24682 (1059) 20403 (894)
100 μM Epi plus 100 μM Fe 238 (13) 2642 (123) 1889 (66)
The table shows NE and Epi-mediated bacterial uptake of 55Fe from 55Fe-labelled transferrin in the presence of concentrations of α-adrenergic 
antagonists inhibitory to NE and Epi growth induction. Exponential cultures of the bacteria shown were inoculated at approximately 2 × 108 CFU/
ml into triplicate 1-ml aliquots of serum-SAPI containing the compounds shown in the Table plus 2.7 × 105 cpm of 55Fe-labelled transferrin. After 
incubation for 6 hours bacteria were harvested, washed and measured for cellular uptake of 55Fe from 55Fe-transferrin (CPM) by scintillation 
counting, as described in Materials and Methods. Analysis of growth levels revealed no significant differences in growth levels between control and 
catecholamine/antagonist supplemented cultures. The values shown represent the means of bacterial 55Fe incorporation from triplicate 1 ml uptake 
assays; standard deviations are shown in brackets.BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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α-Adrenergic antagonist inhibition of bacterial uptake of NE Figure 1
α-Adrenergic antagonist inhibition of bacterial uptake of NE. Washed exponential cultures of E. coli O157:H7, S. enter-
ica, or Y. enterocolitica were added at a cell density of around 2 × 108 CFU/ml to DMEM containing 50 μM NE plus 5 × 105 cpm/
ml of 3H-NE and the following: no additions (Control), or 200 μM phentolamine, phenoxybenzamine or prazosin. Cultures 
were incubated statically for 6 hrs at 37°C in a 5% CO2 humidified incubator, and analysed for growth and 3H-NE uptake as 
described in Materials and Methods. 3H-NE uptake assays were performed in duplicate on at least two occasions; variation 
within individual assay sets was 5% or less, and between experiments no more than 10%. Antagonist supplemented cultures 
showed statistically significant decreases in uptake of 3H-NE (P < 0.001) as compared with the Control.BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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receptors. This differential ability to stimulate one or
other adrenergic receptor subtype ultimately determines
the physiological response of various tissue and organ sys-
tems both to endogenously produced catecholamines and
those administered exogenously for therapeutic interven-
tions.
Although adrenergic and dopaminergic receptors have
been described in other organisms, including the malarial
parasite  Trypanosoma cruzi [15], there have been few
reports examining the presence of such receptors in bacte-
ria. An initial report by Lyte and Ernst [16] concluded that
a non-α, non-β adrenergic receptor mediated process was
responsible for catecholamine-induced growth of Gram-
negative enteric bacteria, including E. coli. More recent in
vivo work by Sperandio and co-workers [17] reported that
both α and β adrenergic antagonists (phentolamine and
propranolol) could block the response of E. coli O157:H7
to Epi and NE, suggesting that the QseC and QseE recep-
tors have catecholamine binding sites with dual α and β
adrenergic catecholamine specificity. Our present report
suggests that bacterial recognition of NE and Epi in the
growth context is mediated by a response system with pri-
marily α-adrenergic specificity, since only the α-antago-
nists phentolamine, prazosin and phenoxybenzamine
were able to block the adrenergic catecholamine growth
induction process. The failure of the β-adrenergic receptor
antagonists propranolol and labetalol to prevent NE and
Epi induction of growth strongly suggests that the
response pathway for these catecholamines is unlikely to
be via either of the previously identified QseC or QseE
receptors. This would also be consistent with the observa-
tion that Y. enterocolitica (in common with the other path-
ogenic Yersinia) does not contain homologs for QseBC or
QseEF, and does not show growth responsiveness to Epi
[24]. That the present results are somewhat in contradic-
tion to the above previous adrenergic receptor reports
[17,18] is not surprising, since our present study used a
different and larger set of α and β receptor antagonists as
well as employing a much wider range of dose-response
curves for both the antagonist as well as bacterial inocula.
This approach was adopted because it is well recognized
that pharmacological characterization of any one adrener-
gic or dopaminergic receptor type or subtype requires the
use of multiple antagonists, employing antagonist:agonist
ratios that examine interaction over a wide dose-response
range especially given that both NE and Epi exhibit multi-
ple potencies for both α and β adrenergic receptors.
Bacterial responses to Dop, an abundant gastrointestinal
catecholamine, were not addressed by either of the above
receptor studies [17,18], and so we investigated whether
Dop induced growth in enteric bacteria through the same
signalling pathways as NE/Epi. The data in Table 4 clearly
show that although a dopaminergic antagonist could
almost completely block growth induction by Dop, it had
no significant effect on NE or Epi responsiveness. These
results indicate that, although the mechanism of
dopamine-induced growth responsiveness in enteric bac-
teria initially appears to be similar to that of NE and Epi,
there are in fact elements in the response pathway for this
catecholamine that are distinct from those involved in NE
or Epi signalling.
Previous studies [3,5,22,25] have shown that on a concen-
tration-dependent basis NE is the most potent growth
stimulator of all of the catecholamines in its ability to
induce the bacterial species examined, inducing in serum-
based media a greater than 3 log increase in cell numbers
at a concentration as low as 10 μM [3,5,22,25]. For Dop
or Epi, concentrations of 20 and 50 μM, respectively, were
required to elicit a similar magnitude of growth stimula-
tion [3,24]. In considering the concentration of catecho-
lamines used in the present and past in vitro studies it
should be emphasized that micromolar concentrations
are meant to mimic the concentrations that may be
present within target organs where in vivo experiments
have shown that intra-synaptic concentrations of NE may
be as high as 10-2 M [26,27]. It is well appreciated that the
level of catecholamines in the blood are within the
nanomolar range; however, these values in large part
reflect spill over from the tissues and therefore grossly
underestimate local effective concentrations, particularly
in the gut [27]. Interestingly, recent reports which have
shown the ability of dopamine to affect the behaviour of
Caenorhabditis elegans have utilized concentrations in the
millimolar range [28,29].
The previously reported lack of growth responsiveness by
Y. enterocolitica to Epi [5,24] is of interest as it indicates
that catecholamines cannot be considered as being agents
which solely mediate access to host Tf/Lf sequestered iron
for bacterial growth. Further experiments from our labora-
tories have demonstrated that not only does Epi fail to
induce growth but that it can also antagonize the growth
inducing effects of both NE and Dop in Y. enterocolitica
[24]. Although the differential action of the adrenergic
and dopaminergic antagonists on Y. enterocolitica
responses indicate that NE and Dop are likely to signal in
Y. enterocolitica via different response pathways (as was
demonstrated for E. coli O157:H7 and S. enterica) the abil-
ity of Epi to specifically antagonize Y. enterocolitica respon-
siveness to both NE and Dop [24] also suggests that the
signalling pathways for these catecholamines must
include common response elements.
Y. enterocolitica shows almost no growth responsiveness to
Epi, and is almost exclusively an enteric pathogen. What
does this tell us about the potential role of neuroendo-
crine hormones in the infectious disease process in theBMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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gut? Within the gastrointestinal tract, the 100 million neu-
rons that comprise the ENS innervate its entire length
[12]. While the presence of adrenergic and dopaminergic
containing neurons has been well documented within the
intestinal tract [12], as well as local production of NE and
Dop [30], there have been no reports of epinephrine con-
taining neurons. The lack of neurons with the ENS con-
taining phenylethanolamine N-methyltransferase, which
is needed for the synthesis of Epi from NE in the catecho-
lamine biosynthetic pathway, is the most likely explana-
tion why epinephrine is not found within the ENS. It has
been proposed [17,18,31] that Epi is the key host-derived
hormonal signal in the pathogenesis of enteric pathogens
such as E. coli O157:H7; however if Epi were present in
concentrations equivalent to those of NE and Dop, the
present results [24] indicate that Y. enterocolitica should
have significant problems in growing within the gut envi-
ronment, which it clearly does not. Based upon the lack of
neurophysiological and anatomical evidence for the pres-
ence of Epi in the gut, it has previously been questioned
whether an infecting bacterium is likely to be exposed to
significant levels of Epi while in the intestinal tract [2]. We
therefore speculate that it is NE, rather than Epi, that is
likely to be the cross-communicating adrenergic signal
molecule between host and enteric pathogens and that
the bacterial response to Epi observed in E. coli O157:H7
[17,18,31] is more likely related to its structural similarity
to NE. Given that specific neuronal innervation in the gut
has been well demonstrated for dopamine [12], our dem-
onstration that it is possible to specifically antagonize
responses to this catecholamine suggest it would be inter-
esting to investigate whether it can also cross communi-
cate with the Qse two-component regulator systems.
Previously, we and others [3,5-7,10,20,25,32-34] have
shown that catecholamines may induce bacterial growth
either through facilitating acquisition of host-sequestered
Fe, which in the case of Gram-negative species requires
both siderophore production and uptake systems, or
through induction of a separate and distinct growth
inducer. We therefore sought to determine if the mecha-
nism of growth inhibition we observed with the adrener-
gic and dopaminergic antagonists involved abrogation of
either or these processes. The results presented in Tables 5
and 6 showed clearly that the α-adrenergic and dopamin-
ergic antagonists did not exert their effects either through
inhibition of catecholamine-Tf complex formation and
subsequent iron mobilization, nor via the siderophore-
dependent processes by which Gram-negative bacteria
assimilate the Tf iron release induced by the catecho-
lamine (if siderophore production had been inhibited
then the uptake of Tf iron would have been reduced, as
occurred in those Table 5 and 655Fe uptake assays con-
ducted in the presence of Fe) [19,22].
Since the mode of action of the adrenergic antagonists did
not appear to be via either of the mechanisms we had pre-
viously shown to be involved in NE/Epi growth induc-
tion, we examined whether they might be acting to block
uptake of the catecholamine. Figure 1 showed that the α-
adrenergic antagonists phentolamine, prazosin and phe-
noxybenzamine all reduced bacterial uptake of 3H-NE.
Although this data points to a possible mechanism by
which the adrenergic antagonists may be blocking cate-
cholamine responsiveness (for instance, inhibition of a
specific catecholamine uptake system), incorporation of
3H-NE into the cell was never completely blocked, sug-
gesting for NE at least, that there may be more than a sin-
gle point of entry. Indeed, the low molecular weight and
structural polarity of NE does not preclude its entry into
the bacterial cell by a non-specific uptake route, such as a
porin, though comparison of 3H-NE levels in an OmpA
mutant showed no difference to wildtype (data not
shown). Previously, we showed that the outer membrane
receptor energizer protein TonB is an essential element in
the siderophore-dependent process by which E. coli
acquires Fe from Tf-catecholamine complexes [19]. More
recently, we have found evidence that TonB may also play
a role in NE uptake, since cellular levels of 3H-NE in an E.
coli O157:H7 TonB mutant was less than half that of its
wildtype parent. Interestingly, Sperandio et al have also
suggested that there might be an outer membrane recep-
tor for NE, though this seems at odds with their observa-
tion that a tonB mutant showed normal induction of LEE
in response to NE [31].
Previously, using 3H-NE-labelled enteropathogenic E. coli
we demonstrated that the majority of assimilated NE is
contained within the cytoplasmic/periplasmic fraction
[21]. Using more precise cell fractionation methods we
found that for enterohemorrhagic E. coli and S. enterica
the location of internalized 3H-NE was again principally
within the cytoplasm, with around 10–15% of the total
cellular levels of 3H-NE present in the periplasmic space.
Others have reported that that AI-3 and Epi appear to be
recognized by the same outer membrane receptor, but
that response to AI-3 and Epi required their transportation
to the periplasm where they interact with the appropriate
sensor kinase to activate gene expression [31]. Osmotic
shocking the cultures in Figure 1 revealed that there was
little difference in the periplasmic:cytoplasmic cellular
ratio of incorporated 3H-NE between control and antago-
nist treated bacteria, indicating that there was no specific
inhibition by the antagonist of the movement of 3H-NE
through the outer membrane to the periplasm, and sug-
gesting that the antagonists were acting to reduce total cel-
lular uptake of NE.
If it is presumed that the mechanisms of catecholamine
growth induction are largely conserved between E. coliBMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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O157:H7, S. enterica and Y. enterocolitica, then the com-
bined data obtained from the experiments described in
this report can be used to make predictions about the
response elements that are likely to be involved in cate-
cholamine-mediated growth induction. The differences in
the specificity of adrenergic antagonist effects between our
study reported herein and those of Sperandio and co-
workers [31] indicates that the previously described two
component regulator systems QseBC and QseEF are
unlikely to be involved in the NE/Epi response pathways
which lead to growth induction. We have not excluded the
possibility that other as yet unidentified two component
regulator systems may be involved; however, the decrease
in bacterial uptake of NE in the presence of adrenergic
antagonists suggests instead that their mechanism of
action could be at the level of blocking uptake of catecho-
lamine into the cell. If, as our data indicates, this blocking
effect is at the level of catecholamine entry into the cyto-
plasm then we can infer that it is in the cytoplasm that the
catecholamines then interact with a response regulator to
induce growth. As we observe differential specificity in the
effects of the adrenergic and dopaminergic antagonists
this would necessitate two separate inner membrane
uptake systems; an adrenergic uptake system for NE and
Epi, and a dopaminergic uptake system for Dop. A single
cytoplasmic response regulator that would recognize all
three catecholamines would explain the results for E. coli
and S. enterica, though in the case of Y. enterocolitica it
would require that the homologous regulator had a differ-
ent binding specificity such that it responds to NE and
Dop but is blocked by the action of Epi [24]
In addition to the possibility of a cytoplasmic response
regulator we have also considered that the uptake of the
catecholamines could have a purely metabolic effect. As
already noted, siderophore synthesis is an essential ele-
ment in the Tf-dependent mechanism of catecholamine
growth induction in Gram-negative bacteria [19,22]. In a
serum- and blood based medium where Fe is actively
withheld from the bacteria by Tf, it could be envisaged
that an excess of an aromatic compound could potentially
be recycled to chorismate and then channelled into the
production of large amounts of enterobactin or yersinia-
bactin which would facilitate Fe uptake and promote
growth. To investigate this possibility we have tested the
ability of NE, Epi and Dop to rescue two E. coli mutants
(aroD and aroK) that are deficient in the pathway to chor-
ismate that is common for both enterobactin and the aro-
matic amino acids. None of the catecholamines could
rescue the aro mutants in a simple growth assay using an
amino acid free minimal medium indicating that, at least
in E. coli, there is no direct pathway which could be used
to recycle the catecholamine hormones to chorismate and
then to enterobactin in order to promote bacterial growth.
Considered collectively, the data clearly indicates that the
bacterial growth response to catecholamines involves
more than the simple provision of host-derived iron that
was identified in our earlier work. The evidence from the
antagonist experiments indicates the presence of specific
recognition systems for NE, Epi and Dop that are essential
for induction of bacterial growth. Differential effects of
the adrenergic antagonists indicate that these response
elements are distinct from the NE- and Epi-responsive
two-component regulator systems that have already been
identified [18,31]; however, unequivocal evidence for the
existence of bacterial α-adrenergic and dopaminergic
uptake systems or receptors specific for growth induction
awaits the results of further mutant analysis and micro-
array work, which are currently underway in our laborato-
ries.
Methods
Bacterial strains and growth conditions
Recent clinical and reference isolates of Yersinia enterocol-
itica isolates were obtained from Dr. Paddy Kimmit of the
Leicester Public Health Laboratory, Leicester UK. Salmo-
nella enterica strain SL1344 was obtained from Dr. Jay
Hinton, Institute of Food Research, Norwich, UK. E. coli
O157:H7 strain NCTC12900 was used previously [19].
Serum-SAPI medium was prepared as described previ-
ously [5,6] and had the following composition: 6.25 mM
NH4NO3, 1.84 mM KH2PO4, 3.35 mM KCl, 1.01 mM
MgSO4and 2.77 mM glucose, pH 7.5, supplemented with
30% (v/v) adult bovine serum) (Sigma, Poole, UK). Apo-
forms of human transferrin (Tf), apomorphine, chlorpro-
mazine, haloperidol, labetalol, phenoxybenzamine,
phentolamine, prazosin, propranolol, raclopride and
yohombine, epinephrine, dopamine and norepinephrine
were all purchased from Sigma, Poole, UK. 55FeCl3 (IES,
specific activity 5 mCi/mg Fe), 3H-NE (TRK584, l-[7,8-3H]
norepinephrine) were obtained from Amersham Life Sci-
ence, UK. The relative specificities of the various antago-
nists used in this study for adrenergic and dopaminergic
receptors are shown in Table 1.
Catecholamine response and antagonism assays
Catecholamine antagonism assays were performed in
serum-SAPI medium supplemented with concentrations
of the compounds shown in the text. A serum-based
medium was employed to more closely approximate in
vivo conditions within a mammalian host [2]. Controls
comprised equivalent volumes of the solvent used to dis-
solve the catecholamine or the antagonist. To determine
whether an antagonist was directly inhibitory to bacterial
growth, all antagonism of catecholamine-growth induc-
tion assays were also performed in the presence of a con-
centration of Fe which overcomes the Fe-limitation of
serum-SAPI medium (100 μM Fe(NO3)3) and allows max-
imal bacterial growth [21]. Unless stated otherwise, bacte-BMC Microbiology 2007, 7:8 http://www.biomedcentral.com/1471-2180/7/8
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ria were inoculated into serum-SAPI at approximately 50–
100 CFU per ml. The final concentration of the bacterial
inoculum was determined by standard pour-plate analysis
using Luria agar. Cultures were incubated statically at
37°C in a 5% CO2 humidified incubator for 18 hours in
the case of E. coli O157:H7 and S. enterica and for 40
hours for Y. enterocolitica isolates since prior reports exam-
ining growth rate of E. coli and Y. enterocolitica in serum-
based medium have shown a slower growth rate for Y.
enterocolitica as compared to E. coli [5]. At the end of the
incubation period cultures were thoroughly re-suspended
by vigorous pipetting and numbers of bacteria enumer-
ated by standard pour plate analysis using Luria agar as
previously described [21]. All growth response assays were
carried out in duplicate, and all experiments were per-
formed on at least two separate occasions. Where appro-
priate, statistical analysis was performed using an
unpaired t-test in which a two-tailed P value was calcu-
lated (Instat program, GraphPad Software, San Diego,
CA). Statistical significance was defined as a P value of less
than 0.05.
Analysis of effects of adrenergic and dopaminergic 
antagonists on catecholamine-mediated bacterial uptake 
of iron from transferrin (Tf)
55Fe-Tf was prepared as described previously by incuba-
tion of apo-Tf with 55FeCl3 using sodium citrate as the iron
donor [21]. Since concentrations of antagonist were used
which inhibit growth response to NE and Epi by at least 2
log orders, the use of actively metabolizing bacteria was
required to examine the ability of catecholamine receptor
antagonists to affect catecholamine-mediated uptake of
iron from transferrin. As such, bacteria were inoculated
into serum-SAPI medium at the higher cell density of 108
CFU per ml. Cultures were then supplemented with 3 ×
105 counts per minute (cpm) of 55Fe-Tf and catecho-
lamines and receptor antagonists added at the concentra-
tions indicated in the figure legends. Cultures were
incubated at 37°C in a 5% CO2 humidified incubator for
6 hrs, following which cells were harvested by centrifuga-
tion at 5000 × g for 5 minutes, washed in PBS and assayed
for cell numbers and 55Fe incorporation using standard
pour plate analysis and scintillation counting as described
previously [21]. Assays were performed in triplicate on at
least two occasions; variation within individual assay sets
was less than 5%, and between experiments was usually
less than 10%.
Analysis of the effects of α-adrenergic antagonists on 
bacterial uptake of NE
Exponential cultures of E. coli O157:H7, S. enterica, or Y.
enterocolitica  were harvested, washed twice in DMEM
medium (Sigma, Poole, UK), and added at a cell density
of approximately 2 × 108 CFU per ml to 10 ml of fresh
DMEM containing 50 μM NE plus 5 × 105 cpm per ml of
3H-NE and the following: no additions (control), or 200
μM phentolamine, phenoxybenzamine or prazosin. Cul-
tures were incubated statically for 6 hrs at 37°C in a 5%
CO2 humidified incubator (this incubation period was
determined by conducting a prior time course of 3H-NE
uptake and represents the time required for maximal
uptake). Cells were then further analyzed for growth and
3H-NE uptake as described for the 55Fe incorporation
assays above. 3H-NE uptake assays were performed in
duplicate on at least two occasions; variation within indi-
vidual assay sets was 5% or less, and between experiments
no more than 15%.
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